

Starting from a background in the radiochemistry of Transition Metals at JRC-Institute for Transuranium Elements (Karlsruhe, Germany), Luca Menichetti (LM) moved his interests in the field of tracer chemistry for medical applications for the development of radiopharmaceuticals at the National Research Council Institute of Clinical Physiology (CNR IFC) in Pisa (IT). In 2005 he achieves the European Certification for the Responsibility of the production and quality control of radiopharmaceuticals from the European Association of Nuclear Medicine and has been appointed Responsible of the GMP Laboratory for Quality Control of radiopharmaceuticals at CNR-IFC. In 2006 LM achieves the PhD in “Design, Drug Development and Bio- Pharmaceutical Testing” at the University of Pisa, while in 2014 LM achieves the Specialization in Clinical Biochemistry at the Faculty of Medicine of the University of Pisa.

LM started his independent research career as a Researcher of the Italian National research country at the Institute of Clinical Physiology (Pisa) in 2000; he became a Full researcher in 2009. Now LM leads a research group with expertise in molecular imaging, MRI and nanotherapeutics. In 2014, LM participated in the creation of the pan European consortium Eurobimaging for the Italian node in Pisa to contribute to the area of molecular imaging. These opportunities led him to initiate a research program on innovative molecular imaging and nanomedicine approaches, leading him to establish a network linking the CNR in conjunction with the G.Monasterio Foundation Hospital in Pisa to enable translation to pre-clinical and clinical studies. LM expertise in molecular imaging, tracer chemistry and nanomedicine has over the years attracted the attention of industrial collaborators who have used the facility in Pisa to advance their development of multidisciplinary research programs.

In the last eight years, the know-how in tracer-chemistry has been extended to other imaging modalities, such as Magnetic Resonance Spectroscopy exploiting the hyperpolarization of  $^{13}\text{C}$ -molecules and the development of novel multimodality based on nanostructured multifunctional materials. In 2008 LM is the Scientific Coordinator for the production of hyperpolarised tracers using Dynamic Nuclear Polarisation for spectroscopic imaging of  $^{13}\text{C}$  at Fondazione CNR/Regione Toscana "G.Monasterio" (Pisa) and CNR Institute of Clinical Physiology (Pisa). The pioneering activity on  $^{13}\text{C}$  spectroscopy started with the acquisition of one of the first commercial polariser (Hypersense, Oxford Instruments) and the research activity has been oriented to the development of kinetic modelling and exploring complementary pathways metabolism.

From 2009 to 2016 LM is designated elected member of the Institute Scientific Board of CNR IFC. Since 2013 LM is a contract Professor at the Department of Chemistry at the University of Pisa and since 2015 is a contract Professor at the Department of Pharmacy at the University of Siena: LM is the scientific coordinator of national projects in the field of nanomedicine and is working in the frame of national and international projects and is author of more than ISI 110 publication.


# Curriculum Vitae



## Personal information

First name / Surname	Luca Menichetti		
Address(es)	65, Via Cittadella, 56019, Nodica, Italy		
Telephone(s)	+39 050 315 2137	Mobile:	+39 3487219552
Fax(es)	+39 050 315 2166		
E-mail	luca.menichetti@ifc.cnr.it		
Nationality	Italian		
Date of birth	01/03/1971		

**Autorizzo l'ISS e l'Associazione NanoInnovation al trattamento dei miei dati personali e la loro conservazione ai fini organizzativi e amministrativi, secondo quanto previsto dal Regolamento UE 2016/679**

Signature:  data 26 August 2022